MedDRA preferred term

Bone loss: adverse event reports recording this term

14,986 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

14,986
reports recording the term: 0.1% of all reports; 329
reports, 12 months to June 2026: 660 in the 12 months before; 91.3%
marked serious by the reporter: 57.4% across all reports; 1.6%
record death among outcomes, as reported: 9.1% across all reports

14,986 reports in FDA's adverse event database record the MedDRA term "Bone loss": 0.1% of all reports received between October 2004 and June 2026. Coders pick the term that best matches the reporter's description.

329 reports recorded it in the 12 months to June 2026, down 50% from 660 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 91.3% are marked serious, 1.6% include death among the outcomes and 9.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Truvada, Viread and Atripla. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	9,098	23.5%
Viread	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	7,073	32.1%
Atripla	—	4,542	25.2%
Stribild	Cytochrome P450 3A inhibitor	2,144	24.5%
Complera	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	1,562	23.9%
Prolia	RANK ligand inhibitor	461	0.3%
Fosamax	Bisphosphonate	323	0.9%
Humira	—	209	0%
Zometa	—	174	0.7%
Forteo	Parathyroid hormone analog	150	0.1%
Enbrel	Tumor necrosis factor blocker	128	0%
Nexium	Proton pump inhibitor	121	0.1%
Prednisone	Corticosteroid	94	0.1%
Kaletra	Cytochrome P450 3A inhibitor	91	1%
Aredia	—	82	2.7%
Boniva	—	82	0.5%
Alendronate sodium	Bisphosphonate	69	0.4%
Methotrexate	Folate analog metabolic inhibitor	69	0%
Revlimid	Thalidomide analog	56	0%
Fosamax Plus D	—	49	2%
Actemra	Interleukin-6 receptor antagonist	47	0.1%
Actonel	Bisphosphonate	45	0.7%
Ibuprofen	Nonsteroidal anti-inflammatory drug	43	0.1%
Rituximab	CD20-directed cytolytic antibody	41	0%
Reclast	Bisphosphonate	38	0.4%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	10,670	13.2%	0%
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	7,090	9.8%	0%
Cytochrome P450 3A inhibitor	2,248	4.8%	0%
Bisphosphonate	509	0.5%	0.2%
RANK ligand inhibitor	503	0.3%	0.2%
Corticosteroid	201	0%	0%
Proton pump inhibitor	190	0%	0%
Tumor necrosis factor blocker	159	0%	0%
Parathyroid hormone analog	152	0.1%	0.1%
Opioid agonist	91	0%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20%2

2 to 110.1%9

12 to 170.1%15

18 to 4419.5%2,917

45 to 6437.2%5,573

65 to 745.8%869

75 and over2.2%325

Age not given35.2%5,276

Patient sex

Female37.8%5,663

Male57.5%8,611

Not given4.8%712

Grey bar: all 20,646,523 reports in the database. 94.8% of these reports give the United States as the country.

Questions about "Bone loss"

What does "Bone loss" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record bone loss?

14,986 reports through June 2026 (0.1% of all reports), 329 of them in the latest 12 months.

Which drugs appear most often in these reports?

Truvada (9,098), Viread (7,073), Atripla (4,542), Stribild (2,144) and Complera (1,562). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.